USPTO Art Unit 1636 Prosecution Statistics

Art Unit Information

Art Unit: 1636
Group: 1630
Tech Center: 1600
Total Cases: 11,530
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19300113COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDAugust 2025January 2026Allow510NoNo
19233142COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13AJune 2025December 2025Allow610YesNo
19232045TYPE V CAS PROTEINS AND APPLICATIONS THEREOFJune 2025October 2025Allow401YesNo
19194571COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDApril 2025November 2025Allow710NoNo
19194480COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDApril 2025November 2025Allow610YesNo
19187484COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDApril 2025November 2025Allow710NoNo
19092639APTAMER AND RIBOZYME EQUILIBRIUM SHIFTING (ARES) RNA CIRCUITS AND USES THEREOFMarch 2025March 2026Allow1111NoNo
19092801COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMarch 2025October 2025Allow710YesNo
19085903Compositions and Methods for NK-92 Cells Expressing Native CD16March 2025March 2026Allow1221NoNo
19083361Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using SameMarch 2025January 2026Allow1011YesNo
19070094COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13AMarch 2025November 2025Allow911YesNo
19066066EXPRESSION SYSTEM FOR PRODUCT MANUFACTURINGFebruary 2025September 2025Allow611YesNo
19064383NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORSFebruary 2025July 2025Allow510NoNo
19060511NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORSFebruary 2025September 2025Allow711NoNo
19056056COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONSFebruary 2025June 2025Allow310NoNo
19054315CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USEFebruary 2025March 2026Allow1330NoNo
19054728TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOFFebruary 2025January 2026Allow1221NoNo
19052052Methods and Compositions for Treatment of Polycystic Kidney DiseaseFebruary 2025November 2025Allow911NoNo
19048826LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOFFebruary 2025September 2025Allow710NoNo
19028916METHODS FOR SEQUENCING SAMPLESJanuary 2025July 2025Allow610NoNo
19028930Product, system and method of cell cultivationJanuary 2025December 2025Allow1111YesNo
19028692Compositions and Methods for Kallikrein (KLKB1) Gene EditingJanuary 2025August 2025Allow710YesNo
19025939COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDSJanuary 2025November 2025Abandon1010NoNo
19010571SMALL RNA-BASED DRUG, PREPARATION AND USE THEREOF IN PROPHYLAXIS AND/OR TREATMENT OF CARDIOMYOPATHYJanuary 2025September 2025Allow921NoNo
18959371SUPPLEMENTATION OF LIVER ENZYME EXPRESSIONNovember 2024November 2025Allow1211YesNo
18941863Controllable TranscriptionNovember 2024July 2025Allow811NoNo
18939430SNP LOCUS COMBINATION FOR PATERNITY TESTING, DETECTION PRIMER PAIRS AND APPLICATION THEREOFNovember 2024September 2025Abandon1001NoNo
18934005COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024November 2025Allow1220NoNo
18934041COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18933567COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933750COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933499COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933645COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18932248COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1320NoNo
18909918MODIFIED DOUBLE-STRANDED RNA AGENTSOctober 2024April 2025Allow610NoNo
18896055COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024November 2025Allow1320NoNo
18891208COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024October 2025Allow1320YesNo
18891221COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024October 2025Allow1320YesNo
18891189COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024April 2025Allow720YesNo
18889137COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024February 2025Allow510YesNo
18885005Compositions and Methods Using CPG OligonucleotidesSeptember 2024April 2025Allow711NoNo
18885261METHODS OF TREATMENT OF SCN2A-RELATED DISORDERSSeptember 2024January 2026Allow1620YesNo
18830722ENGINEERED sgRNA DESIGN AND PREPARATION METHODSeptember 2024August 2025Allow1122YesNo
18814067MODIFIED DOUBLE-STRANDED RNA AGENTSAugust 2024January 2025Allow510NoNo
18807709VIRAL VECTOR AND RECOMBINANT SIMIAN ADENOVIRUSAugust 2024December 2025Abandon1620NoNo
18807591COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSIONAugust 2024November 2024Allow301NoNo
18805534TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGNAugust 2024January 2025Allow510YesNo
18805023METHODS AND COMPOSITIONS FOR MODULATING A GENOMEAugust 2024May 2025Allow911NoNo
18799681SYSTEM AND PROCESS FOR IN VIVO MANUFACTURING NANOSTRUCTURE-ENDED DOUBLE-STRANDED COVALENTLY-CLOSED LINEAR DNA, THE RESULTING MOLECULES AND THEIR USESAugust 2024September 2025Allow1311YesNo
18797394TREATMENT OF MST1 RELATED DISEASES AND DISORDERSAugust 2024March 2025Allow711NoNo
18834523Recombinant Humanized Collagen Type I Alpha-1 (rhCol1A1), and Expression Vector and Use ThereofJuly 2024April 2025Allow810NoNo
18789158ENGINEERED GUIDE SCAFFOLDSJuly 2024October 2025Allow1421YesNo
18777597SPLIT COMPLEMENTARY BASE EDITING SYSTEMS BASED ON BIMOLECULAR DEAMINASES AND USES THEREOFJuly 2024April 2025Allow901YesNo
18730678METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTSJuly 2024August 2025Allow1320YesNo
18758151METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUSJune 2024July 2025Allow1320NoNo
18755579COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATESJune 2024August 2025Allow1421NoNo
18750444RECOMBINANT EXPRESSION VECTOR FOR HIGH EXPRESSION OF BRAZZEIN IN SACCHAROMYCES CEREVISIAE AND METHOD FOR MASS-PRODUCTION OF BRAZZEIN USING THE SAMEJune 2024February 2026Allow2010NoNo
18743724RECOMBINANT PARTICLE PROTEIN PRODUCT SUITABLE FOR INDUSTRIAL PRODUCTION AND PREPARATION METHOD THEREFORJune 2024May 2025Allow1120YesNo
18744370LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDSJune 2024March 2025Allow910YesNo
18737778IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION, AND CHIMERIC ANTIGEN RECEPTORJune 2024December 2025Abandon1821NoNo
18669712ENDONUCLEASE SYSTEMSMay 2024May 2025Allow1111YesNo
18665736MGAT1 DEFICIENT CELLS AND USES THEREOFMay 2024October 2025Allow1721YesNo
18661524NCOVSHRNA*2RBD DRUG FOR TARGETED DELIVERY SHRNA by RBD, SYNTHESIS METHOD, AND APPLICATION THEREOFMay 2024November 2025Abandon1931NoNo
18660147COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYMay 2024September 2025Allow1731YesNo
18653253SMALL INTERFERING RNA TARGETING CFB AND USES THEREOFMay 2024December 2025Abandon1930NoNo
18653454BASE EDITING ENZYMESMay 2024August 2025Allow1511YesNo
18640396CONTAMINATION CONTROL WHEN GROWING GREEN ALGAEApril 2024August 2025Abandon1630NoNo
18702749GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCYApril 2024March 2026Allow2310NoNo
18612868DETECTION OF NUCLEIC ACID AND NON-NUCLEIC ACID TARGET MOLECULESMarch 2024July 2024Allow410NoNo
18607256Circular RNA For Translation In Eukaryotic CellsMarch 2024October 2025Allow1940YesNo
18604547Inducible Promoter for Rice Expression System, Synthetic Biological Platform and Use ThereofMarch 2024March 2025Allow1220NoNo
18597673RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASESMarch 2024December 2024Allow1010YesNo
18594132COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFMarch 2024October 2024Allow820NoNo
18591645GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIESFebruary 2024March 2025Abandon1210NoNo
18591760GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIESFebruary 2024March 2025Abandon1210NoNo
18590737COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDSFebruary 2024November 2025Abandon2001NoNo
18586689COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOFFebruary 2024January 2025Allow1110NoNo
18586417TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGNFebruary 2024August 2024Allow511NoNo
18430378METHOD FOR PRECISELY PREPARING CIRCULAR RNA WITH ANABAENA INTRON SELF-CLEAVING RIBOZYMEFebruary 2024August 2024Allow610NoNo
18429059ASSAYS AND METHODS TO ASSIST IN VITRO FERTILIZATIONJanuary 2024September 2025Allow1941YesNo
18428353TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)January 2024April 2025Allow1501NoNo
18426444RAAV-BASED COMPOSITIONS AND METHODSJanuary 2024January 2026Allow2411NoNo
18425204SEQUENCE SPECIFIC ANTIMICROBIALSJanuary 2024January 2025Allow1210YesNo
18418774METHODS FOR SEQUENCING SAMPLESJanuary 2024October 2024Allow911YesNo
18418781METHODS FOR SEQUENCING SAMPLESJanuary 2024November 2024Allow1011YesNo
18416945RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)January 2024September 2025Allow2020NoNo
18410136NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERYJanuary 2024May 2024Allow410NoNo
18410720ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGENJanuary 2024August 2025Abandon1901NoNo
18393974ADAPTER FOR USE IN A PLANETARY MIXERDecember 2023April 2025Allow1630NoNo
18392905CASZ COMPOSITIONS AND METHODS OF USEDecember 2023December 2024Allow1211NoNo
18393408miRNA Switches for RNA-Triggered Control of RNA InterferenceDecember 2023March 2025Allow1530YesNo
18390233LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENEDecember 2023June 2025Abandon1801NoNo
18543966COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOFDecember 2023February 2025Abandon1421NoNo
18544160Circular RNA For Translation In Eukaryotic CellsDecember 2023August 2025Allow2020NoNo
18534974COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDSDecember 2023June 2024Allow610NoNo
18534489METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCEDecember 2023March 2024Allow300YesNo
18533538METHODS FOR SEQUENCING SAMPLESDecember 2023October 2024Allow1110YesNo
18532043CONTAMINATION CONTROL WHEN GROWING YEASTSDecember 2023January 2025Allow1350YesNo
18527576ELECTROPORATION, DEVELOPMENTALLY-ACTIVATED CELLS, PLURIPOTENT-LIKE CELLS, CELL REPROGRAMMING AND REGENERATIVE MEDICINEDecember 2023October 2025Abandon2331NoNo
18523558COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENENovember 2023May 2025Abandon1801NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1636.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
131
Examiner Affirmed
81
(61.8%)
Examiner Reversed
50
(38.2%)
Reversal Percentile
74.7%
Higher than average

What This Means

With a 38.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1062
Allowed After Appeal Filing
211
(19.9%)
Not Allowed After Appeal Filing
851
(80.1%)
Filing Benefit Percentile
6.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1636 - Prosecution Statistics Summary

Executive Summary

Art Unit 1636 is part of Group 1630 in Technology Center 1600. This art unit has examined 11,530 patent applications in our dataset, with an overall allowance rate of 53.5%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1636's allowance rate of 53.5% places it in the 10% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1636 receive an average of 2.06 office actions before reaching final disposition (in the 64% percentile). The median prosecution time is 36 months (in the 26% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.